Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016 (2016), Article ID 4342820, 6 pages
http://dx.doi.org/10.1155/2016/4342820
Case Report

Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura

Department of Hematology, Eiju General Hospital, 2-23-16 Higashi-Ueno, Taito-ku, Tokyo 110-8645, Japan

Received 30 March 2016; Revised 9 June 2016; Accepted 10 July 2016

Academic Editor: Kazunori Nakase

Copyright © 2016 Masao Hagihara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Cooper and J. Bussel, “The pathogenesis of immune thrombocytopaenic purpura,” British Journal of Haematology, vol. 133, no. 4, pp. 364–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. W. Saif, J. L. Hopkins, and S. D. Gore, “Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia,” Leukemia & Lymphoma, vol. 43, no. 11, pp. 2083–2092, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Kyle, R. V. Pierre, and E. D. Bayrd, “Multiple myeloma and acute myelomonocytic leukemia,” The New England Journal of Medicine, vol. 283, no. 21, pp. 1121–1125, 1970. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Govindarajan, S. Jagannath, J. T. Flick et al., “Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma,” British Journal of Haematology, vol. 95, no. 2, pp. 349–353, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Cuzick, S. Erskine, D. Edelman, and D. A. G. Galton, “A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults,” British Journal of Cancer, vol. 55, no. 5, pp. 523–529, 1987. View at Publisher · View at Google Scholar · View at Scopus
  6. L. E. Roeker, D. R. Larson, R. A. Kyle, S. Kumar, A. Dispenzieri, and S. V. Rajkumar, “Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients,” Leukemia, vol. 27, no. 6, pp. 1391–1393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Mailankody, R. M. Pfeiffer, S. Y. Kristinsson et al., “Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS),” Blood, vol. 118, no. 15, pp. 4086–4092, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Akashi, M. Harada, T. Shibuya et al., “Simultaneous occurrence of myelomonocytic leukemia and multiple myeloma: involvement of common leukemic progenitors and their developmental abnormality of ‘lineage infidelity’,” Journal of Cellular Physiology, vol. 148, no. 3, pp. 446–456, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Economopoulos, V. Pappa, A. Panani et al., “Myelopathies during the course of multiple myeloma,” Haematologica, vol. 76, no. 4, pp. 289–292, 1991. View at Google Scholar · View at Scopus
  10. R. Rios Tamayo, F. Sole, and F. Gascon, “Simultaneous occurrence of the 5q-syndrome and multiple myeloma,” Clinical and Laboratory Haematology, vol. 22, no. 1, pp. 49–51, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. G. A. Kastanas, C. A. Papaioannou, and H. A. Nathena, “Multiple myeloma and acute leukemia,” Acta Haematologica, vol. 62, no. 2, pp. 78–80, 1979. View at Google Scholar · View at Scopus
  12. I. Raz and A. Polliack, “Coexistence of myelomonocytic leukemia and monoclonal gammopathy or myeloma. Simultaneous presentation in three patients,” Cancer, vol. 53, no. 1, pp. 83–85, 1984. View at Publisher · View at Google Scholar · View at Scopus
  13. A. C. Parker, “A case of acute myelomonocytic leukaemia associated with myelomatosis,” Scandinavian Journal of Haematology, vol. 11, no. 4, pp. 257–260, 1973. View at Google Scholar · View at Scopus
  14. B. Cleary, R. A. Binder, A. N. Kales, and B. J. Veltri, “Simultaneous presentation of acute myelomonocytic leukemia and multiple myeloma,” Cancer, vol. 41, no. 4, pp. 1381–1386, 1978. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Taddeini and W. Schrader, “Concomitant myelomonocytic leukemia and multiple myeloma,” Minnesota Medicine, vol. 55, no. 5, pp. 446–448, 1972. View at Google Scholar · View at Scopus
  16. L. Parapia, C. R. Abbott, G. Masters, and B. E. Roberts, “Simultaneous presentation of acute myelomonocytic leukaemia and multiple myeloma,” Acta Haematologica, vol. 68, no. 2, pp. 153–156, 1982. View at Google Scholar · View at Scopus
  17. K. Shibata, Y. Shimamoto, S. Nakazato, M. Matsuzaki, and J. Tadano, “Refractory anaemia with ringed sideroblasts concurrent with multiple myeloma—a brief review of the recent literature,” Haematologia, vol. 28, no. 4, pp. 199–205, 1997. View at Google Scholar · View at Scopus
  18. G. J. Mufti, T. J. Hamblin, G. P. Clein, and C. Race, “Coexistent myelodysplasia and plasma cell neoplasia,” British Journal of Haematology, vol. 54, no. 1, pp. 91–96, 1983. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Copplestone, G. J. Mufti, T. J. Hamblin, and D. G. Oscier, “Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy,” British Journal of Haematology, vol. 63, no. 1, pp. 149–159, 1986. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Annino, P. Martino, P. Barsotti, P. Serra, V. Marinozzi, and F. Mandelli, “Multiple myeloma and acute myelomonocytic leukemia: simultaneous occurrence without previous chemotherapy,” Acta Haematologica, vol. 64, no. 4, pp. 195–200, 1980. View at Google Scholar · View at Scopus
  21. T. M. Grogan, B. G. M. Durie, C. M. Spier, L. Richter, and E. Vela, “Myelomonocytic antigen positive multiple myeloma,” Blood, vol. 73, no. 3, pp. 763–769, 1989. View at Google Scholar · View at Scopus
  22. J. Epstein, H. Xiao, and X.-Y. He, “Markers of multiple hematopoietic-cell lineages in multiple myeloma,” The New England Journal of Medicine, vol. 322, no. 10, pp. 664–668, 1990. View at Publisher · View at Google Scholar · View at Scopus
  23. F. G. Rosado, W. G. Morice, R. He, M. T. Howard, M. Timm, and E. D. Mcphail, “Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process,” British Journal of Haematology, vol. 169, no. 3, pp. 368–376, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Hadjadj, M. Michel, M.-P. Chauveheid, B. Godeau, T. Papo, and K. Sacre, “Immune thrombocytopenia in chronic myelomonocytic leukemia,” European Journal of Haematology, vol. 93, no. 6, pp. 521–526, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. U. Kalina, W.-K. Hofmann, S. Koschmieder et al., “Alteration of c-mpl-mediated signal transduction in CD34+ cells from patients with myelodysplastic syndromes,” Experimental Hematology, vol. 28, no. 10, pp. 1158–1163, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Brierley and D. P. Steensma, “Thrombopoiesis-stimulating agents and myelodysplastic syndromes,” British Journal of Haematology, vol. 169, no. 3, pp. 309–323, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Svensson, O. Chowdhury, H. Garelius et al., “A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine,” European Journal of Haematology, vol. 93, no. 5, pp. 439–445, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Prica, M. Sholzberg, and R. Buckstein, “Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials,” British Journal of Haematology, vol. 167, no. 5, pp. 626–638, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. N. Saleh, J. B. Bussel, G. Cheng et al., “Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study,” Blood, vol. 121, no. 3, pp. 537–545, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Will, M. Kawahara, J. P. Luciano et al., “Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome,” Blood, vol. 114, no. 18, pp. 3899–3908, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. C. L. Erickson-Miller, J. Kirchner, M. Aivado, R. May, P. Payne, and A. Chadderton, “Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag,” Leukemia Research, vol. 34, no. 9, pp. 1224–1231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Harada, M. Watanabe, K. Suzuki et al., “Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality,” International Journal of Hematology, vol. 90, no. 3, pp. 353–360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Fenaux, A. Giagounidis, D. Selleslag et al., “A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q,” Blood, vol. 118, no. 14, pp. 3765–3776, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Raza, J. A. Reeves, E. J. Feldman et al., “Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q,” Blood, vol. 111, no. 1, pp. 86–93, 2008. View at Publisher · View at Google Scholar
  35. R. Buckstein, R. Kerbel, M. Cheung et al., “Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis,” Leukemia Research, vol. 38, no. 7, pp. 756–763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Adès, M. A. Sekeres, A. Wolfromm et al., “Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine,” Leukemia Research, vol. 37, no. 6, pp. 609–613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. M. A. Sekeres, R. V. Tiu, R. Komrokji et al., “Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes,” Blood, vol. 120, no. 25, pp. 4945–4951, 2012. View at Publisher · View at Google Scholar · View at Scopus